Soluble implantable device comprising polyelectrolyte with hydrophobic counterions
AssigneeAbbott Cardiovascular Systems Inc.
InventorsSyed F. A. Hossainy, Mikael O. Trollsas, Lothar W. Kleiner
Life of this patent
Estimating the term…
Abstract
The present invention provides an implantable device having a biosoluble coating or a biosoluble body structure comprising a polyelectrolyte and a counterion and the methods of making and using the same.
Claims24
An implantable device, comprising a biosoluble body structure and optionally comprising a coating deposited upon the body structure of the implantable device, the biosoluble body structure or comprising:
- a complex comprising a polyelectrolyte and a counterion, the counterion being p-propylbenzenesulfonate.
An implantable device, comprising a biosoluble body structure formed of a material that is sparingly soluble in an aqueous medium,
- the biosoluble body structure comprising:
- a complex comprising a polyelectrolyte and a counterion, the counterion being p-propylbenzenesulfonate.
A method of fabricating an implantable device, comprising
- forming a biosoluble body structure comprising:
- a complex comprising a polyelectrolyte and a counterion, the counterion being p-propylbenzenesulfonate.
A method of fabricating an implantable device, comprising
- forming a biosoluble body structure comprising:
- a complex comprising a polyelectrolyte and a counterion, the counterion being selected from the group consisting of p-propylbenzenesulfonate, nonyl acid, and combinations thereof;
- wherein the body structure further comprises a bioactive agent, the bioactive agent being selected from paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-0-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), 7-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin, fenofibrate, and combinations thereof.
Dependencies are inferred from the claim text.